eosinophilic esophagitis Archives - Vista Partners LLC

Biotech’s Bullish Blueprint: Jazz Pharmaceuticals Buys Actio For ~$1.3B, While Eupraxia Builds for Scale -( $EPRX $JAZZ $XBI )

by John F. Heerdink, Jr. 5 days ago 132Views 0Likes

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) offer investors two distinctly attractive versions of the same biotech proposition: value creation through disciplined execution. Jazz is deploying capital to deepen an established rare-epilepsy franchise, while Eupraxia is assembling the…

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 598Views 0Likes

Yes indeed, Eupraxia Pharmaceutical's (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time. A Chronic Disease Finally Meets a Long-Term Plan Eosinophilic…

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

by John F. Heerdink, Jr. March 2, 2026 595Views 0Likes

In a conference season dominated by mega-cap immunology franchises, Eupraxia Pharmaceuticals (NASDAQ: EPRX) quietly walked into AAAAI 2026 and walked out looking a lot less “micro‑cap” and a lot more “mispriced asset.” For investors willing to do more than skim the abstracts,…

Tag: eosinophilic esophagitis

Biotech’s Bullish Blueprint: Jazz Pharmaceuticals Buys Actio For ~$1.3B, While Eupraxia Builds for Scale -( $EPRX $JAZZ $XBI )

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI )

Your Guide To Staying Informed In The Markets